This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Letendre, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Letendre, S. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2000, p. 2173-2175, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Indinavir Population Pharmacokinetics in Plasma and Cerebrospinal Fluid

Scott L. Letendre,1,* Edmund V. Capparelli,2 Ronald J. Ellis,1 J. Allen McCutchan,1 and The HIV NEUROBEHAVIORAL RESEARCH CENTER GROUP

HIV Neurobehavioral Research Center1 and Pediatric Pharmacology Research Unit,2 University of California, San Diego, California

Received 10 August 1999/Returned for modification 16 December 1999/Accepted 25 April 2000

Plasma and cerebrospinal fluid (CSF) indinavir concentrations were measured by high-performance liquid chromatography. The median concentration in plasma exceeded that in CSF 10-fold. The modeled CSF curve was flat at 155 nM, and the estimated ratio of the areas under the CSF and plasma concentration-time curves was 6%. We conclude that CSF indinavir concentrations are lower than levels in plasma but exceed the clinical 95% inhibitory concentration range.

* Corresponding author. Mailing address: HIV Neurobehavioral Research Center, University of California, San Diego, 150 W. Washington St., San Diego, CA 92103. Phone: (619) 543-4730. Fax: (619) 543-1235. E-mail: sletendre{at}ucsd.edu.

Antimicrobial Agents and Chemotherapy, August 2000, p. 2173-2175, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • DiCenzo, R., DiFrancesco, R., Cruttenden, K., Donnelly, J., Schifitto, G. (2009). Lopinavir Cerebrospinal Fluid Steady-State Trough Concentrations in HIV-Infected Adults. The Annals of Pharmacotherapy 43: 1972-1977 [Abstract] [Full Text]  
  • Lodise, T. P., Nau, R., Kinzig, M., Drusano, G. L., Jones, R. N., Sorgel, F. (2007). Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother 60: 1038-1044 [Abstract] [Full Text]  
  • Strain, M. C., Letendre, S., Pillai, S. K., Russell, T., Ignacio, C. C., Gunthard, H. F., Good, B., Smith, D. M., Wolinsky, S. M., Furtado, M., Marquie-Beck, J., Durelle, J., Grant, I., Richman, D. D., Marcotte, T., McCutchan, J. A., Ellis, R. J., Wong, J. K. (2005). Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy. J. Virol. 79: 1772-1788 [Abstract] [Full Text]  
  • Csajka, C., Marzolini, C., Fattinger, K., Decosterd, L. A., Telenti, A., Biollaz, J., Buclin, T. (2004). Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus. Antimicrob. Agents Chemother. 48: 3226-3232 [Abstract] [Full Text]  
  • Ohe, T., Sato, M., Tanaka, S., Fujino, N., Hata, M., Shibata, Y., Kanatani, A., Fukami, T., Yamazaki, M., Chiba, M., Ishii, Y. (2003). EFFECT OF P-GLYCOPROTEIN-MEDIATED EFFLUX ON CEREBROSPINAL FLUID/PLASMA CONCENTRATION RATIO. Drug Metab. Dispos. 31: 1251-1254 [Abstract] [Full Text]  
  • Pfister, M., Labbe, L., Hammer, S. M., Mellors, J., Bennett, K. K., Rosenkranz, S., Sheiner, L. B. (2003). Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. 47: 130-137 [Abstract] [Full Text]  
  • Solas, C., Lafeuillade, A., Halfon, P., Chadapaud, S., Hittinger, G., Lacarelle, B. (2003). Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother. 47: 238-243 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»